Scientist Anthony Heymann receives the Breakthrough Award 2023

Dew Point Remedies, Inc. Announced that biomolecular scientist Anthony (Tony) Hyman, co-founder of Dewpoint Therapeutics and director of Max Planck Institute for Molecular Cell Biology and Genetics (MPI-CBG)on me 2023 Breakthrough Award in Life Sciences To discover a new mechanism of cellular regulation mediated by phase separation of proteins and RNA into membraneless liquid droplets called condensers. Anthony Heymann is the recipient of the 2023 Breakthrough Award with Dr. Clifford Brangwyn of Princeton University and Howard Hughes Medical Institute, and a former postdoctoral researcher in Dr. Heymann’s lab at the Max Planck Institute.

Dr. Hyman co-founded Dewpoint Therapeutics in 2019 to investigate the role of capacitors in driving diseases such as cancer and neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), and to apply this breakthrough understanding of biomolecular capacitors to transform previously discovered therapeutics. Indestructible targets.

“We are exceptionally proud, and not at all surprised, to see continued global recognition of the incredible research conducted by the co-founder, which is the foundation of our work at Dewpoint. Because of Tony’s early insight, Dewpoint applies our understanding of dysregulation in biomolecular capacitors to drive a revolutionary approach to drug discovery,” he said. Dr. Amit Nathwani, CEO of Dewpoint, “There is a huge, previously unexplored potential for developing new therapies for patients in many therapeutic areas.”

Dr. Isaac Klein, Chief Scientific Officer at Dewpoint, added, “Tony’s research has led to an entirely new understanding of biology. It has changed the way we think about the origin and treatment of diseases. Dewpoint advances this learning to identify new targets and mechanisms of action across multiple biological pathways to develop treatments for conditions and targets. which was previously thought insurmountable. This will likely be the next big leap in drug discovery and have a real impact on patients’ lives.”

Heymann is a founding member of the Max Planck Institute for Molecular Cell Biology and Genetics (MPI-CBG), which he continues to lead today with a team of directors. He won the EMBO Gold Medal in 2003 and was elected as a teammate of British Royal Society Since 2007. In 2011, Hyman was awarded the Gottfried Wilhelm Leibniz Prize and in 2018, the Schleiden Medal from German National Academy of Sciences Leopoldina. In 2019, Hyman received the Carl Zeiss Lecture for his outstanding achievement in Cell Biology and was elected as an international member of the National Academy of Sciences. In 2020, he was one of the recipients of the Wiley Prize in Biomedical Sciences. He has been a member of the German National Academy of Sciences Leopoldina since 2021. He has been awarded the 2022 Körber European Science Prize, the 2022 Hope Funds for Cancer Research Award for Basic Science, and the 2023 Breakthrough Prize for Life Sciences. In 2019, Tony co-founded Dewpoint Therapeutics with Dr. Richard Young The Whitehead Institute at the Massachusetts Institute of Technology, With Dr. Philip Sharp as the founding chair of the Scientific Advisory Board.

source: dew point treatments

Pictures: dew point treatments